Please wait while the transcript is being prepared...
I'm Professor Mark Cragg.
I'm a Professor of Experimental
Cancer Biology at the Center for
Cancer Immunology in Southampton.
I'm going to talk about "Monoclonal
Antibodies in Haemato- Oncology".
So as a brief introduction summary of what
I'm going to talk about today, in essence,
it's about the antibody
revolution where we've come from.
From a number of decades ago
where we had very few antibodies
in the treatment of medicine.
I'm going to give you
a case study in Rituximab,
which is the first monoclonal antibody
that's approved in haematology.
And in fact in all oncology, then I'm
going talk through some of the work that's
been done looking at the mechanisms
of action of monoclonal antibodies in
human oncology and the mechanisms of
resistance that we've now encountered.
And then, talking about some of the
strategies that we might use to try and
overcome that resistance and
that largely comes down to
using monoclonal antibodies
in various combinations.
And then, I'll have a little speculation
at the end in terms of the future and
where we're going with
some of these strategies.
So the antibody revolution really
started in the late 1990's.
In that decade really we'd got six
approved monoclonal antibodies.
Some of those were fully mouse monoclonals
and therefore had a limited utility
in humans, but
now we've got as high as over 70 approved
monoclonal antibodies that we use to
treat human beings for various diseases.
And the exciting thing is they're still
more in clinical development, and
soon to be approved.
So we have hundreds of monoclonal
antibodies in phase I and II trials and
a similar number, probably in phase III
trials that may get approved next year.
So we're looking at probably getting
to 100 in the next few years.